Novartis: Geographic Atrophy trials

The registry lists 15 Geographic Atrophy studies with Novartis as lead sponsor. 1 are open to participants now and 11 have results posted.

Phase 1 2Phase 2 4Phase 3 3Phase 4 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular DegenerationRecruitingNCT07441642Phase 2
• Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)CompletedNCT05269966Phase 4Results posted
• Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.CompletedNCT04774926Phase 4Results posted
• Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular DegenerationCompletedNCT04679935Phase 4Results posted
• An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) StudyCompletedNCT04597632Phase 3Results posted
• Study of Brolucizumab in Adult Patients With Suboptimal Anatomically Controlled Neovascular Age-related Macular DegenerationCompletedNCT04264819Phase 3Results posted
• Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)CompletedNCT04005352Phase 3Results posted
• Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular EdemaCompletedNCT03927690Phase 2Results posted
• Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMDCompletedNCT02161575Phase 4Results posted
• A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD PatientsCompletedNCT02130024Phase 4Results posted
• Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)CompletedNCT01775124Phase 4Results posted
• Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)CompletedNCT01527500Phase 2Results posted
• A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationCompletedNCT05230537Phase 2
• A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema PatientsCompletedNCT04635800Phase 1
• Intravitreal LFG316 in Patients With Advanced Age-related Macular DegenerationCompletedNCT01255462Phase 1